comparemela.com

Latest Breaking News On - தொடங்கப்பட்டது கட்டம் - Page 1 : comparemela.com

Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Interim Results and Business Updates

Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Interim Results and Business Updates
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Published: Mar 09, 2021 –Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021– –Up to 8 clinical data readouts expected over next 18 months– –Management to host conference call at 8:30 a.m. ET– CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020.

Evelo Biosciences, Inc : Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

(2) -Announced new positive data in human experimental model of inflammation of EDP1815- -Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021- -Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021- -Up to 8 clinical data readouts expected over next 18 months- -Management to host conference call at 8:30 a.m. ET- CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.